We are live on
!
Find out more
SL
Siren LLC Portfolio holdings
AUM
$3.61B
1-Year Est. Return
203.3%
This Fund
S&P 500
This Quarter
Est. Return
+22.99%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2B
AUM Growth
–
Cap. Flow
+$1.96B
Cap. Flow
% of AUM
97.94%
Top 10 Holdings %
Top 10 Hldgs %
41.25%
Holding
112
New
112
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$131M |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$101M |
| 3 |
Scholar Rock
SRRK
|
+$98.9M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$80.3M |
| 5 |
BCAX
Bicara Therapeutics
BCAX
|
+$78.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.5% |
| 2 | Technology | 2.87% |
| 3 | Communication Services | 1.83% |
| 4 | Consumer Discretionary | 0.77% |
| 5 | Real Estate | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kymera Therapeutics
KYMR
$8.94B
| $141M | 7.03% |
+2,969,733
| New | +$131M |
|
|
ONC
2
BeOne Medicines Ltd
ONC
$39.4B
| $126M | 6.32% |
+563,314
| New | +$101M |
|
|
3
Scholar Rock
SRRK
$6.44B
| $90.2M | 4.51% |
+11,259,438
| New | +$98.9M |
|
|
BCAX
4
Bicara Therapeutics
BCAX
$1.84B
| $78.3M | 3.91% |
+3,072,827
| New | +$78.4M |
|
5
argenx
ARGX
$54.1B
| $77.9M | 3.89% |
+143,647
| New | +$72.6M |
|
6
Crinetics Pharmaceuticals
CRNX
$8.92B
| $66.9M | 3.35% |
+1,309,652
| New | +$67.5M |
|
|
RNAM
7
DELISTED
Avidity Biosciences
RNAM
| $66.2M | 3.31% |
+1,440,736
| New | +$62.5M |
|
|
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
| $62.5M | 3.12% |
+2,167,224
| New | +$80.3M |
|
9
Lexicon Pharmaceuticals
LXRX
$1.1B
| $61.1M | 3.05% |
+38,918,903
| New | +$69.3M |
|
|
IGMS
10
DELISTED
IGM Biosciences
IGMS
| $55.1M | 2.75% |
+3,330,422
| New | +$36.5M |
|
|
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
| $52.1M | 2.6% |
+3,258,677
| New | +$39.9M |
|
12
Ascendis Pharma A/S
ASND
$16.8B
| $51.9M | 2.6% |
+347,921
| New | +$47M |
|
|
SLN
13
Silence Therapeutics
SLN
$564M
| $51.5M | 2.57% |
+2,831,770
| New | +$52.7M |
|
14
Arrowhead Research
ARWR
$12.4B
| $47.6M | 2.38% |
+2,458,778
| New | +$60M |
|
15
Wave Life Sciences
WVE
$1.2B
| $46.9M | 2.35% |
+5,721,172
| New | +$34.2M |
|
|
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
| $44.1M | 2.21% |
+1,377,701
| New | +$51.5M |
|
17
Dyne Therapeutics
DYN
$4.9B
| $40.8M | 2.04% |
+1,134,664
| New | +$45.2M |
|
18
Vera Therapeutics
VERA
$2.36B
| $37M | 1.85% |
+837,928
| New | +$31.8M |
|
19
Neumora Therapeutics
NMRA
$302M
| $34.4M | 1.72% |
+2,606,571
| New | +$30.4M |
|
20
Vaxcyte
PCVX
$8.64B
| $34.3M | 1.71% |
+299,991
| New | +$27M |
|
21
Revolution Medicines
RVMD
$44B
| $34.2M | 1.71% |
+753,601
| New | +$32.8M |
|
|
MRUS
22
DELISTED
Merus
MRUS
| $34.1M | 1.7% |
+682,201
| New | +$35.6M |
|
23
Taboola.com
TBLA
$1.11B
| $33.5M | 1.67% |
+9,969,495
| New | +$32.9M |
|
|
LBPH
24
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $30.1M | 1.51% |
+903,227
| New | +$31.1M |
|
25
Xenon Pharmaceuticals
XENE
$6.12B
| $29.3M | 1.46% |
+743,769
| New | +$30M |
|
Similar funds
SCM
ACM
GCM
VI
BPS
VPC
WWA
OCM
Siren LLC's Q3 2024 Portfolio in Review
Q3 2024 is the first quarter with a 13F filing on record for Siren LLC, which disclosed 112 positions worth $2B. Its ten largest holdings account for 41% of the portfolio.
Its largest position is Kymera Therapeutics: 2,969,733 shares worth $141M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Technology and Communication Services.
- Siren LLC's largest Q3 2024 buy was Kymera Therapeutics: 2,969,733 shares worth $141M.
- Siren LLC's ten largest holdings make up 41% of its $2B portfolio in Q3 2024.
- Siren LLC disclosed 112 positions in Q3 2024, its first 13F filing on record.
Based on Siren LLC's 13F filing for Q3 2024, filed 13 Nov 2024.